IGLV3-17

Across TCGA pan-cancer cohorts, IGLV3-17 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of IGLV3-17’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where IGLV3-17 RNA is repressed in tumor relative to normal tissue. In most cancer types IGLV3-17 is over-expressed in tumor, although a few such as COAD and READ show the opposite, repressed pattern.

COAD, READ, and LUAD are the cancer types where IGLV3-17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGLV3-17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	IV	−0.898	<.001	10	view →
READ	All	All	−0.891	<.001	7	view →
LUAD	All	II,III,IV	+0.526	<.001	7	view →
HNSC	Female	II,III,IV	+0.106	.049	1	view →
KIRC	All	All	+0.101	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

IGLV3-17–COAD

Open the COAD breakdown →